ApoE4 exacerbates Alzheimer's‐like pathologies in T2DM by activating GSK‐3β and disrupting insulin signaling, leading to tau hyperphosphorylation, neuroinflammation, and cognitive decline. Here, MAPT is linked to type 2 diabetes mellitus.